• On 9 April 2026, Tempus AI, Inc. announced an expanded multi-year collaboration giving Gilead Sciences enterprise-wide access to its AI-driven Lens platform and broader multimodal oncology datasets, alongside integrated Tempus analytical services.
• This deepened data and platform access positions Tempus more firmly inside Gilead’s oncology R&D workflows, embedding its technology in trial design, biomarker strategy, and real-world evidence generation across multiple cancer programs.
• We’ll now examine how Tempus granting Gilead enterprise-wide access to its Lens platform could influence the company’s longer-term investment narrative.

Uncover the next big thing with 33 elite penny stocks that balance risk and reward.

Tempus AI Investment Narrative Recap

To own Tempus AI, you have to believe its AI and data platforms can become embedded in how clinicians and drug developers make decisions, eventually supporting a path toward profitability. The expanded Gilead collaboration deepens pharma integration but does not, on its own, change the core near term tension between strong forecast revenue growth and continued losses, with the key risk remaining whether Tempus can convert heavy R&D and capex spending into improving margins before investor patience thins.

Among recent updates, the ALERT trial with Medtronic stands out in light of the Gilead news, because it showcases Tempus’ AI being used in real-world clinical workflows to close treatment gaps. Together, ALERT and the Lens expansion give investors tangible examples of Tempus’ platforms being used across both provider and pharma settings, which matters for the bullish catalyst that recurring data and software contracts could become a larger, higher-margin share of revenue over time.

Yet behind the promise of deeper pharma integration and hospital adoption, investors should also understand how reliant Tempus remains on large, multiyear data licensing deals and what happens if those renewals...

Tempus AI's narrative projects $2.3 billion revenue and $358.5 million earnings by 2029. This requires 22.0% yearly revenue growth and a $603.5 million earnings increase from -$245.0 million today.

Uncover how Tempus AI's forecasts yield a $77.93 fair value, a 81% upside to its current price.

Exploring Other Perspectives

Some analysts were far more optimistic before this news, assuming about 31.7% annual revenue growth to roughly US$2.5 billion by 2029, which contrasts with the uncertainty around large data contracts and shows how your view on the Gilead expansion could shift whether that upbeat scenario still feels realistic.

Explore 13 other fair value estimates on Tempus AI - why the stock might be worth 10% less than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Tempus AI research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Tempus AI research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Tempus AI's overall financial health at a glance.

Curious About Other Options?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Invest in the nuclear renaissance through our list of 93 elite nuclear energy infrastructure plays powering the global AI revolution.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.